New companies sometimes take years to get enough momentum to support an expansion. Ten23 health is not one of them. With today’s announcement of plans for a new facility, the CDMO is expanding twice before it celebrates its first birthday.
The company plans to establish a new 5,000-square-meter manufacturing facility in Visp, Switzerland, where it operates a former swissfillon site. The new digs will include sterile manufacturing lines plus laboratories, offices and technical areas across four floors.
Ten23 expects construction on the building to be complete by this summer and the production site to be operational by 2024. The project will create around 100 jobs and allow the company to add around 30 million units in annual filling capacity, ten23 said.
The company acquired its existing site in Visp from swissfillon in October 2021. The site is licensed to make prefilled syringes, vials and other types of medicines for both marketed and investigational therapies.
The news comes just a few months after ten23’s expansion announcement in March, when the company said it will add 1,000 square meters to its Visp site for visual inspection procedures, cold storage, device assembly operations, labeling and more.
Ten23 health launched last September and was financed by 3i Group of London. It aims to support biotech startups as well as established pharmaceutical customers in injectable development and manufacturing.